A novel strategy for defining critical amino acid residues involved in protein/glycosaminoglycan interactions.
about
Transglutaminase-2 interaction with heparin: identification of a heparin binding site that regulates cell adhesion to fibronectin-transglutaminase-2 matrixHuman immunodeficiency virus and heparan sulfate: from attachment to entry inhibitionLaminin 332 processing impacts cellular behaviorThe signal peptide of Staphylococcus aureus panton valentine leukocidin LukS component mediates increased adhesion to heparan sulfatesIdentification of heparin-binding sites in proteins by selective labeling.Identification of amino acid residues important for heparan sulfate proteoglycan interaction within variable region 3 of the feline immunodeficiency virus surface glycoprotein.The HIV-1 envelope glycoprotein gp120 features four heparan sulfate binding domains, including the co-receptor binding site.Mapping the epitopes of antibodies.Heparan sulfate proteoglycans: structure, protein interactions and cell signaling.A beginner's guide to chemokines.Heparan sulfate targets the HIV-1 envelope glycoprotein gp120 coreceptor binding site.Heparan Sulfate Proteoglycans Promote Telomerase Internalization and MHC Class II Presentation on Dendritic Cells.Glycosaminoglycanomics: where we are.Cell surface proteoglycans syndecan-1 and -4 bind overlapping but distinct sites in laminin α3 LG45 protein domain.Tyrosine dephosphorylation of the syndecan-1 PDZ binding domain regulates syntenin-1 recruitment.Heparan sulfate regulates ADAM12 through a molecular switch mechanism.The morphogenic properties of oligomeric endostatin are dependent on cell surface heparan sulfate.Solution structure of CXCL13 and heparan sulfate binding show that GAG binding site and cellular signalling rely on distinct domains.
P2860
Q24309155-030AAC8B-BA76-4BB6-A515-92ABC0679271Q27004059-ECAB99B4-9EDF-47F2-A837-2701B96C0783Q27021764-13884ADB-C8C1-4F7E-948F-6916CFE8D1A1Q28475214-2858E8F3-03F6-411F-8390-92F985C35526Q33476610-D490A549-68F9-4295-AD8B-515917FDB8E4Q35077801-1D2ED2B6-4B79-4747-B4C3-6595C88B7460Q35674470-28AD15D5-9665-42F6-A404-F03959294203Q37024671-A00606E6-97EF-4E84-BE1F-C5B0B58BA026Q37590177-FE144900-02C0-4A28-AA72-F25E8C58CEE8Q38008721-7128BC3E-D6FE-4A91-A44E-11E90AF10E7FQ38328705-8537687C-02B1-43E5-9091-257E9A913446Q38754328-D678A1FE-32F3-4A11-A924-178C83B0D1A6Q39143849-EFCF14B5-3204-422F-93F9-6733882BEB94Q39393046-0463EAC3-3505-4394-979B-CFBDEBD42363Q39882042-33C05296-EF40-4F32-BB8A-328D01441E5AQ39938427-ECAC27EB-662D-4C04-A20D-3974F7A4FFFAQ40315779-5053DCFF-E063-4DA9-802F-8798854766ABQ45071009-1C95FFF6-A0A7-4D29-991E-4FC2E3011370
P2860
A novel strategy for defining critical amino acid residues involved in protein/glycosaminoglycan interactions.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
A novel strategy for defining ...... lycosaminoglycan interactions.
@en
type
label
A novel strategy for defining ...... lycosaminoglycan interactions.
@en
prefLabel
A novel strategy for defining ...... lycosaminoglycan interactions.
@en
P2093
P2860
P356
P1476
A novel strategy for defining ...... lycosaminoglycan interactions.
@en
P2093
Elodie Crublet
Hugues Lortat-Jacob
Jean-Pierre Andrieu
Romain R Vivès
P2860
P304
54327-54333
P356
10.1074/JBC.M409760200
P407
P577
2004-10-12T00:00:00Z